Effect of TET2 gene mutation on the curative efficacy of myelodysplastic syndromes in children
10.3760/cma.j.cn115356-20191022-00209
- VernacularTitle:TET2基因突变对儿童骨髓增生异常综合征疗效的影响
- Author:
Yubao BAI
1
;
Dianzhi WANG
;
Zhanying WANG
;
Wenpeng HAO
;
Ying WANG
;
Yunxing XIE
;
Binghong HAN
;
Jun MA
Author Information
1. 哈尔滨市第一医院血液病肿瘤研究所 150010
- From:
Journal of Leukemia & Lymphoma
2020;29(7):415-418
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the therapeutic effect of low-dose arsenous acid/tretinoin with or without low-dose cytarabine induction regimen on myelodysplastic syndromes (MDS) with TET2 gene mutation in children.Methods:Nine children with MDS who were hospitalized at the First Hospital of Harbin from March 2009 to April 2018 were collected, including 3 cases of refractory cytopenia of childhood (RCC), 4 cases of MDS with excess of blasts type Ⅰ (MDS-EBⅠ) and 2 cases of MDS with excess of blasts type Ⅱ (MDS-EBⅡ). The next-generation gene sequencing method (NGS) was applied to detect the TET2 gene mutation in bone marrow cells of children with MDS. The low-dose arsenous acid/tretinoin with or without low-dose cytarabine induction regimen was adopted to conduct tiered therapy on children with MDS. The clinical efficacy was assessed in line with the MDS response evaluation criteria adopted by the MDS International Working Group (IWG) in 2006.Results:Among the 9 patients, the short-term clinical efficacy was observed in 8 cases. Two patients with TET2 gene mutation achieved the short-term clinical efficacy of bone marrow complete remission (mCR) and hematological improvement (HI). Among 7 patients without TET2 gene mutation, 4 patients obtained CR, 1 patients obtained mCR and HI, and 1 patients obtained stable disease (SD) in terms of the short-term clinical efficacy.Conclusion:The low-dose arsenous acid/tretinoin with or without low-dose cytarabine regimen may be beneficial to MDS children with TET2 gene mutation.
